Insilico Medicine and Taiwan-based Bora Pharmaceuticals announced plans to launch a new AI-driven manufacturing company for biologics. The initiative is designed to compete with service providers headquartered in China and combines Insilico’s generative AI capabilities with Bora’s operational and development manufacturing base, with the partnership framed around governance and execution through definitive agreements.